JPS63170319A - Anticataractous agent - Google Patents
Anticataractous agentInfo
- Publication number
- JPS63170319A JPS63170319A JP62001365A JP136587A JPS63170319A JP S63170319 A JPS63170319 A JP S63170319A JP 62001365 A JP62001365 A JP 62001365A JP 136587 A JP136587 A JP 136587A JP S63170319 A JPS63170319 A JP S63170319A
- Authority
- JP
- Japan
- Prior art keywords
- tannin
- agent
- anticataractous
- glucopyranose
- cataract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001864 tannin Polymers 0.000 claims abstract description 24
- 235000018553 tannin Nutrition 0.000 claims abstract description 24
- 239000001648 tannin Substances 0.000 claims abstract description 24
- 229920001461 hydrolysable tannin Polymers 0.000 claims abstract description 5
- 229940124428 anticataract agent Drugs 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000002075 main ingredient Substances 0.000 claims 1
- 210000000695 crystalline len Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000003889 eye drop Substances 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- QJYNZEYHSMRWBK-NIKIMHBISA-N 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose Chemical compound OC1=C(O)C(O)=CC(C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 QJYNZEYHSMRWBK-NIKIMHBISA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- -1 lipid peroxide Chemical class 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 2
- 230000002899 effect on cataract Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JQQBXPCJFAKSPG-SVYIMCMUSA-N Geraniin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2[C@@H]3OC(=O)C=4C=C(O)C(O)=C5O[C@@]6(O)C(=O)C=C([C@@H](C5=4)C6(O)O)C(=O)O[C@H]4[C@@H]3OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@H]4O2)=C1 JQQBXPCJFAKSPG-SVYIMCMUSA-N 0.000 description 1
- 229920000061 Geraniin Polymers 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- GJMUCSXZXBCQRZ-UHFFFAOYSA-N geraniin Natural products Oc1cc(cc(O)c1O)C(=O)OC2OC3COC(=O)c4cc(O)c(O)c(O)c4c5cc(C(=O)C67OC3C(O6)C2OC(=O)c8cc(O)c(O)c9OC%10(O)C(C(=CC(=O)C%10(O)O)C7=O)c89)c(O)c(O)c5O GJMUCSXZXBCQRZ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
「産業上の利用分野」
本発明はタンニンまたはタンニン成分を主成分とする抗
白内障剤に関する。DETAILED DESCRIPTION OF THE INVENTION "Field of Industrial Application" The present invention relates to an anti-cataract agent containing tannin or a tannin component as a main component.
「従来技術」
タンニンＦｉ植物中に広（分布し、そのｇ分については
数多くの研究がなされている。またその用途としては、
ナメシ剤としての用途が古（から知らハているが、近年
その抗酸化作用が注目され種々の研究がなされている。``Prior art'' Tannin Fi is widely distributed in plants, and many studies have been conducted on its g content.
Although it has been known since ancient times for its use as a sedative, its antioxidant effects have recently attracted attention and various studies have been conducted.
本発明者等は水晶体の酸化障害に対する各種タンニン成
分の抗酸化作用及び作用機序について研究し優′ｒＬｆ
ｃ過酸化脂質除去効果がある事を報告し、ている（あた
らし、い眼科 第２巻１２９３〜１２９６頁、同第３巻
２５４〜２５７頁、他）。The present inventors researched the antioxidant effects and mechanisms of action of various tannin components on oxidative damage to the crystalline lens, and
It has been reported that it has a lipid peroxide removal effect (Atarashi, Ii Ophthalmology Vol. 2, pp. 1293-1296, Vol. 3, pp. 254-257, etc.).
「発明が解決しようとする問題点および問題を解決する
為の手段」
タンニン成分が抗酸化作用を有し優れた過歌化脂質除去
効果があるＪ％が見い比されていふ、しかしながら、タ
ンニン成分が医薬、特に抗白内障剤とし、て利用できる
か否かについての直接的な知見はなく、その研究をする
必要があった。本発明者等はタンニン成分を動物に投与
し、白内障に対する効果ｔｌ−調べｆＣ。"Problems to be Solved by the Invention and Means for Solving the Problems" J%, whose tannin component has an antioxidant effect and has an excellent effect of removing hyperactive lipids, has been compared. There was no direct knowledge as to whether the ingredient could be used as a medicine, especially as an anti-cataract agent, and it was necessary to conduct research. The present inventors administered tannin components to animals and investigated the effect on cataracts.
「発明の開示」
タンニンは天然ｍ物中に広く分布し、て層るポリフェノ
ール誘導体で、その成分につ力て様々研究がなされ、低
分子量ポリフェノール、＠ｄ合型タンニン、７ＩＯ水分
解性タンニンに大別される。タンニンのナメシ剤として
の用途は古くから知られているが、近年その各種成分に
ついての研究がなされている。本発明者等はタンニン成
分が優れた過酸化脂質除去効果があふ−Ｊを見す出し、
さらに医薬としての用途を鋭意研究した結果抗白内障剤
として有ｊ目である＄全見込量した。タンニンには各徨
成分があるが、その内でも原水分解性タンニンに優れた
効果がみられた。白内障は水晶体が混濁して起る病気で
、混濁した水晶体全敗り田り、眼内レンズ全挿入する方
法）がとらｎている。白内障の病因については種々研究
さ几ているが、白内障に対する冷涼効果を判定するのに
、水晶体の混濁程度を測定するのが最も直接的な方法と
なる。後述の薬理試験の項で詳述すｂが、刃口水分解性
タンニンの一種であるペンタ−０−ガロイル−β−Ｄ
−グルコピラノースを遺伝性白内障マウスに投与した所
、水晶体の混濁発現が遅延し、抗白内障剤として有用で
ある事を見い出Ｌ５た。"Disclosure of the Invention" Tannins are polyphenol derivatives that are widely distributed and layered in natural products, and various studies have been conducted on their components. Broadly classified. The use of tannin as a smearing agent has been known for a long time, but in recent years, research has been conducted on its various components. The present inventors have discovered Afu-J, which has an excellent tannin component and has an excellent lipid peroxide removal effect,
Furthermore, as a result of intensive research into its use as a medicinal agent, it was estimated that it would be used as an anti-cataract agent. Tannins have various toxic components, but among them, raw water-degradable tannins were found to have excellent effects. Cataract is a disease caused by the clouding of the crystalline lens, and the method of treatment is to remove the entire clouded lens and insert the entire intraocular lens. Although various studies have been conducted on the etiology of cataracts, the most direct method for determining the cooling effect on cataracts is to measure the degree of opacity of the crystalline lens. b, which will be explained in detail in the pharmacological test section below, is penta-0-galoyl-β-D, which is a type of water-degradable tannin at the cutting edge.
- It was discovered that when glucopyranose was administered to mice with inherited cataracts, the onset of clouding of the crystalline lens was delayed, making it useful as an anti-cataract agent.
タンニン成分としては、ペンタ−０−ガロイル−β−Ｄ
−グルコピラノース、ゲラニインで代表される加水分解
性タンニンが好ブし論が、７１０水分解性タンニンを特
に単離する必要はなく、他の成分と混合したままで投与
してもよい。投与形態としては内服２点眼等が挙げられ
、剤型としては錠剤、散剤、頌粒剤、刀ブセル剤９点眼
液、眼軟膏等が挙げられ、そＡ（’几の剤型に工６じて
医薬として計容１ｆ′Ｌる賦形剤、溶解剤、軟ａ基剤等
を用層る事ができる。投与量につｈては特に限定する必
要はなく９年令、症状等により適宜選択できるが。As a tannin component, penta-0-galoyl-β-D
- Hydrolyzable tannins such as glucopyranose and geraniin are preferred, but it is not necessary to specifically isolate 710 hydrolyzable tannins, and they may be administered as they are mixed with other ingredients. Administrative forms include oral 2-eye drops, etc., and dosage forms include tablets, powders, granules, ophthalmic solutions, eye ointments, etc. Excipients, solubilizers, soft bases, etc. with a total volume of 1f'L can be used as medicines.The dosage does not need to be particularly limited, and can be administered as appropriate depending on the age of 9 years, symptoms, etc. You can choose.
通常内服の場合は１日ＪＯ〜１０００■を数回に分は投
与り１２２点眼場合は０．０１〜５％一度の浴剤または
軟−ｌ：ｉを１日数回投与する。In the case of oral administration, JO ~ 1000 ml is administered several times a day, and in the case of eye drops, 0.01 to 5% bath salt or soft-l:i is administered several times a day.
加水分解性タンニンの一例トして、ペンター０−カロイ
ルーβ−Ｄ−グルコピラノースヲ用いた薬坤試験例及び
製剤ｆｌｌを以下の実施例に示すが。As an example of a hydrolyzable tannin, a drug test example and a formulation using penta-0-caloyl-β-D-glucopyranose are shown in the following examples.
本発明は実施例に限定さ才するものではない。The present invention is not limited to the examples.
「実施例−１
１、薬理試験
生後１４日口の遺伝性白内障マウス（２５匹）ニ０．１
％（重量％）の割合でペンタ−０−ガロイル−β−Ｄ−
グルコピラノースを餌に混合して連日与えた所、水晶体
の混濁は生後２１．１８±２．１２日才で認められなか
った。"Example-1 1. Pharmacological test 14 days old hereditary cataract mice (25 mice) 0.1
% (wt%) of penta-0-galoyl-β-D-
When glucopyranose was mixed with the food and given daily, no clouding of the crystalline lens was observed at the age of 21.18±2.12 days.
−１対照群とり、てペンター０−ガロイル−β−Ｄ−グ
ルコピラノース無投与の遺伝性白内障マウス（１］５匹
）の混濁を観察した所、 ２ （１，（１±１．８６日
に水晶体の混濁が餡められた。2 (1, (1±1.86 days The opacity of the crystalline lens has become thicker.
上記の結果はベンターＯ−ガロイル−β−り一グルコビ
ラノースの効果を示し、ている。このマウスでの結果を
、マウスとヒトとの寿命の差を考慮しヒトに外挿すると
、約１．５ケ月混濁を遅延させることになる。マウスで
は遺伝性白内障が非常に短期間に進行するのに対し、老
人性ヒト白内障ではその進行が緩慢である＄全考慮する
と、ペンタ−Ｏ−ガロイルーβ−Ｄ−グルコピラノース
のヒト白内障に対する効果はさらに大きいものと考えら
几る。The above results demonstrate the effect of venter O-galoyl-β-ri-glucobylanose. If this result in mice is extrapolated to humans, taking into account the difference in lifespan between mice and humans, it will delay opacification by about 1.5 months. In mice, hereditary cataracts progress in a very short period of time, whereas in senile human cataracts, the progression is slow. I thought it was something even bigger.
２、製剤例
１）ベンターＯ−ガロイルーβ−Ｄ−グルコピラノース
、ポリビニルピロリドン、乳糖、結晶セルロースおよび
カルボキシメチルセルロースカルシウムを混合し、常法
により顆粒とした後、ステアリン隙マグネシウムヲ加え
打錠し下記処方の錠剤を得た。2. Formulation Example 1) Venter O-galloyrou β-D-glucopyranose, polyvinylpyrrolidone, lactose, crystalline cellulose and carboxymethyl cellulose calcium were mixed and made into granules by a conventional method, and then stearin gap magnesium was added and tableted to obtain the following formulation. tablets were obtained.
ペンタ−Ｏ−ガロイル−β−Ｄ−グルコピラノース１０
０■
ポリビニルピロリドン ２０■乳
、糖
１６１Ｒｇ結晶セルロース ９２
■カルポキンメチルセルロースカルシクム
２０■計 ２５０
■上記錠剤は通常のフィルムコーティングをしてもよく
、さらに糖衣）ｆ４をコーティングしてもよ論。Penta-O-galoyl-β-D-glucopyranose 10
0 ■ Polyvinylpyrrolidone 20 ■ Milk
,sugar
161Rg crystalline cellulose 92
■Carpoquin Methylcellulose Calcicum
20 ■Total 250
■The above tablets may be coated with a regular film, or even coated with sugar coating) f4.
２）ペンタ−０−４０イル−β−Ｄ−グルコピラノース
、ボリンルベート８０．塩化ナトリウムおよび塩化ペン
ザルコニワムを用い下記処方の点眼剤を得た。2) Pent-0-40yl-β-D-glucopyranose, borine rubate 80. Eye drops having the following formulation were obtained using sodium chloride and penzalkoniwam chloride.
ペンタ−Ｏ−ガロイル−β−Ｄ−グルコピラノース１０
００ｑ
塩化ナトリウム ９（１０”９ポリ
ソルベート８（１２００１１Ｐ
塩化ベンザルコニウム ５ｍ５１精製
水 適量針
１ （１０ｔ／「発明の効
果」
タンニンまたはタンニン成分を白内障治療剤として使用
することにより、水晶体の混濁を遅延させるという効果
を有するものであり、タンニンまたはタンニン成分は抗
白内障剤として有用なものである。Penta-O-galoyl-β-D-glucopyranose 10
00q Sodium chloride 9 (10”9 Polysorbate 8 (120011P Benzalkonium chloride 5m51 Purified water Appropriate amount Needle
1 (10t/"Effects of the Invention") Tannins or tannin components used as a cataract therapeutic agent have the effect of delaying clouding of the crystalline lens, and tannins or tannin components are useful as anti-cataract agents. be.
Claims (3)
内障剤。(1) Anti-cataract agents whose main ingredients are tannins or tannin components.
求の範囲第１項記載の抗白内障剤。(2) The anti-cataract agent according to claim 1, wherein the tannin component is a hydrolyzable tannin.
グルコピラノースである特許請求の範囲第１項記載の抗
白内障剤。(3) Tannin component is penta-O-galoyl-β-D-
The anti-cataract agent according to claim 1, which is glucopyranose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62001365A JPH0623111B2 (en) | 1987-01-07 | 1987-01-07 | Anti-cataract agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62001365A JPH0623111B2 (en) | 1987-01-07 | 1987-01-07 | Anti-cataract agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63170319A true JPS63170319A (en) | 1988-07-14 |
| JPH0623111B2 JPH0623111B2 (en) | 1994-03-30 |
Family
ID=11499470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62001365A Expired - Lifetime JPH0623111B2 (en) | 1987-01-07 | 1987-01-07 | Anti-cataract agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0623111B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100588830B1 (en) | 2004-09-01 | 2006-06-14 | 한불화장품주식회사 | A cosmetic composition for anti-aging containing an extract of melothria heterophylla |
-
1987
- 1987-01-07 JP JP62001365A patent/JPH0623111B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100588830B1 (en) | 2004-09-01 | 2006-06-14 | 한불화장품주식회사 | A cosmetic composition for anti-aging containing an extract of melothria heterophylla |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0623111B2 (en) | 1994-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2048812C1 (en) | Method of treatment of eye inflammatory diseases and agent for treatment of eye inflammatory diseases | |
| KR100403418B1 (en) | Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases | |
| KR950013754B1 (en) | Ophthalmic non-steroid formulations | |
| JP6638092B2 (en) | Use of pyrroloquinoline quinone, its derivatives and / or salts in dry syndrome and pharmaceutical compositions | |
| CA2801145C (en) | N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament | |
| Simon et al. | Long-term oral acyclovir therapy: effect on recurrent infectious herpes simplex keratitis in patients with and without grafts | |
| UA90507C2 (en) | Mucoadhesive formulation useful in medical devices and in pharmaceutical formulations | |
| JP2006176499A (en) | Therapeutic agent for eye disease | |
| US4451477A (en) | Bendazac treatment of cataract | |
| JPH02180820A (en) | Acetyl-l-carnitine cataract treating agent | |
| EP1656131B1 (en) | Use of betaine for treating intermittent claudication | |
| JP2000506833A (en) | Treatment of macula edema | |
| RU2376993C2 (en) | Application of timosaponin b-ii in making drug or product for stroke prevention and treatment | |
| KR950007099B1 (en) | Pharmacentical composition for treatment of cataract | |
| EP0063973B2 (en) | Eye lotion composition based on chondroitin sulfate a | |
| WO2009018333A2 (en) | Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells | |
| EP0191520B1 (en) | (1-phenylmethyl-5-hydroxy-1h-indazol-3-yl)-oxyacetic acid and salts thereof for use as a medicament, and pharmaceutical compositions containing them | |
| Pedrazini et al. | L-lysine as a Possible Supplement for Treatment of Herpetic Epithelial Keratitis: A Case Report and Literature Review | |
| JPS63170319A (en) | Anticataractous agent | |
| US5789446A (en) | Therapeutic agent for treating joint diseases associated with arthritis | |
| EP0131317B1 (en) | Use of benzadac and of its salts for the manufacture of a medicament for the treatment of retinitis pigmentosa | |
| WO2009135432A1 (en) | The use of salvianolic acid b on anti- thrombus | |
| Copello et al. | Ozone therapy in patients with retinitis pigmentosa | |
| EP0402208B1 (en) | Mixture of Vitamin A in physiological dosis and different active ingredients having therapeutic effect | |
| Bar et al. | Presenile cataracts in phenytoin-treated epileptic patients |